실적분석 2026년 8월 3일

UFP Technologies ($UFPT) Q2 2026 Earnings Analysis — Adjusted EPS and Revenue Both Beat Expectations, After-Hours Rally

Earnings Scorecard

Revenue: $174 million (+15.1% year-over-year, vs. $159 million estimate) ✅ Beat

EPS: Adjusted $2.92 (vs. $2.56 estimate) ✅ Beat · GAAP $2.68

Guidance: Not provided — no Q3 or full-year revenue/EPS figures in the press release

Stock reaction: +4.66% after-hours ($280) — as of 06:20 KST, Aug 4

Positives

Beat on both lines: Adjusted EPS of $2.92 and revenue of $174 million exceeded expectations

Record quarter: Revenue, net income, and EPS all at quarterly highs

Improving profitability: Gross margin of 29.3%, operating income up 15.5% year-over-year

UFP Technologies is a contract developer and manufacturer that designs and produces medical devices and sterile packaging, among other products. Q2 2026 revenue of $174 million rose 15.1% from $151 million a year earlier, and organic revenue growth excluding M&A effects was 12.4%, above the $159 million consensus.

Adjusted diluted EPS was $2.92, beating both the prior year's $2.50 and the $2.56 consensus. GAAP diluted EPS was $2.68. Net income (aggregate, with no separate non-controlling-interest breakdown) totaled $20.9 million, up 21.4% from $17.2 million a year ago, while operating income rose 15.5% to $28.1 million. Gross margin improved to 29.3% from 28.8% in the year-ago period.

Negatives

Rising SG&A: SG&A grew 21.8%, lifting its share of revenue to 13.1%

U.S. margin pressure: Dominican Republic investment is weighing on near-term product mix and margins

Non-medical softness: The non-medical business held roughly flat year-over-year

SG&A was $22.8 million, up 21.8% from $18.7 million a year earlier, and its share of revenue rose from 12.4% to 13.1%. Adjusted SG&A as a percentage of revenue also climbed to 11.7% from 10.8%, reflecting spending tied to growth and organizational capacity build-out.

President and CEO Mitch Rock explained that the Dominican Republic investment is delivering early operational benefits, but the gains are coming through more slowly than expected, creating short-term product-mix and margin pressure in the U.S. business. The non-medical business was roughly flat, while growth was concentrated in the top five customers (+14.7%) and the rest of the MedTech segment (+19.7%). Cash declined from year-end, while accounts receivable and inventory rose, pointing to a notable working-capital burden.

What Management Said

Management characterized Q2 and first-half results as demonstrating execution across the business and progress on the long-term growth strategy. They emphasized that revenue growth, gross margin expansion, and operating income gains came from the strength and diversification of the MedTech segment.

Looking ahead, they cited existing customer expansion, new program launches, disciplined M&A, and investments in people and capabilities as opportunities. However, the press release contained no Q3 or full-year revenue/EPS guidance, and management acknowledged that the Dominican Republic investment is taking longer than expected to pay off, suggesting U.S. margin pressure could persist near term. The tone was execution-focused, blending confidence with caution.

Market Reaction and What to Watch Next

With adjusted EPS and revenue both above expectations, a quarterly record, and double-digit organic growth confirmed, the market appears to be re-embracing the growth-and-margin story. Improving gross margins and balanced growth across MedTech customers appear to have offset the negatives of higher SG&A and U.S. margin pressure. Even without specific guidance, the underlying strength of the print appears to have driven buying.

Monitor when and how much the Dominican Republic production transfer and investment relieve U.S. margin pressure.

Watch whether top customers and new robotic-surgery and program revenues sustain double-digit growth into Q3.

Track how the rising SG&A ratio and working-capital build (accounts receivable and inventory) constrain earnings and cash flow.